To the OMX
Announcement No. 41-07 / Copenhagen, 6 December 2007

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen Ø
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com

TopoTarget Announces Award of Two Key Patents

- Valproic acid patent granted in US -
- HDAC patent granted in Europe -

Copenhagen, Denmark – 6 December 2007 – TopoTarget A/S (OMX: TOPO) announced today that it has been granted a key patent in the US covering the use of Valproic acid (VPA) to treat the major cancer types. Additionally the company has been awarded an important HDAC patent in Europe.

The VPA patent US 7,265,154 is valid until February 2022 and covers the use of VPA and close derivatives against the major types of cancer. A corresponding patent has already been granted in Europe and is pending in other territories.

"The granting of this patent gives us an extremely strong patent position not just for skin diseases but also for other cancer indications, for our VPA franchise of products of BACECA®, AVUGANE™ and Savicol™, which are in Phase II development treating skin diseases and Familial Adenomatous Polyposis (FAP) which leads to colorectal cancer." Said Professor Peter Buhl Jensen, CEO of TopoTarget A/S. "The clinical data we have collected to now supports our belief that there is a clear opportunity in repurposing VPA in order to help patients with different types of skin cancer including Basal Cell Carcinoma where we recently published positive Phase II data."

Additionally the HDAC patent application EP1492534 has been allowed and has broad claims to a class of hydroxamic acids comprising a piperazine linkage as histone deacetylase (HDAC) inhibitors and their use in proliferative diseases such as cancer and psoriasis. This application is currently pending in all major territories, has been granted in New Zealand and allowed in Mexico. The claims in this application cover the HDAC compound PX118490 which has been out-licensed to LEO Pharma A/S for development as an anti-psoriasis drug. TopoTarget's lead product in clinical development, belinostat, is covered by other patents in the company's IP estate.

"This HDAC patent adds to our already very comprehensive global patent estate covering our HDAC library," said Professor Peter Buhl Jensen, Chief Executive Officer of TopoTarget A/S. "A robust IP position is key in our on-going strategy to develop new effective oncology therapies that can be brought to the market to help to treat patients who need them."

TopoTarget has a number of HDAC inhibitors in clinical and pre-clinical development, including belinostat, which is currently in Phase II trials for a number of cancer indications.

Today's news does not change TopoTarget's full-year financial guidance for 2007.

TopoTarget A/S

For further information, please contact:

Dr. Peter Buhl Jensen	Telephone	+45 39 17 83 41
Chief Executive Officer	Mobile	+45 21 60 89 22
Ulla Hald Buhl	Telephone	+45 39 17 83 92
Director IR & Communications	Mobile	+45 21 70 10 49

Background information

About HDAC inhibitors
HDAC inhibitors are a class of therapeutics with a novel mechanism of action that target HDAC enzymes involved in the regulation of multiple key processes in cancer and inflammatory diseases as well as other indications. HDAC inhibitors function by altering levels of gene transcription and have been shown to have multiple effects on cancer cells including growth arrest (also in drug resistant subtypes), induction of apoptosis or programmed cell death, promotion of cellular differentiation and inhibition of angiogenesis. HDAC inhibitors can also overcome drug resistance by re-sensitizing chemotherapy resistant cancer cells to treatment, and in combination with other anti-cancer agents, produce synergy in their anti-tumour effects.

About TopoTarget
TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with subsidiaries in the US, Switzerland, Germany and the UK, dedicated to finding ''Answers for Cancer'' and developing improved cancer therapies. TopoTarget is founded and run by clinical cancer specialists and combines years of hands-on clinical experience with in-depth understanding of the molecular mechanisms of cancer. Focus lies on highly predictive cancer models and key cancer targets (including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors) and a strong development foundation has been built. TopoTarget has a broad portfolio of small molecule pre-clinical drug candidates and nine drugs (both small molecules and protein based) are in clinical development, including both novel anti-cancer therapeutics and new cancer indications for existing drugs. Savene™/Totect™ was approved by EMEA in 2006 and the FDA in 2007 and is TopoTarget's first product on the market. For more information, please refer to www.topotarget.com.

TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements about our expectations of the progression of our preclinical and clinical pipeline including the timing for commencement and completion of clinical trials and with respect to cash burn guidance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. TopoTarget cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors, including, but not limited to, the following: The risk that any one or more of the drug development programs of TopoTarget will not proceed as planned for technical, scientific or commercial reasons or due to patient enrolment issues or based on new information from non-clinical or clinical studies or from other sources; the success of competing products and technologies; technological uncertainty and product development risks; uncertainty of additional funding; TopoTarget's history of incurring losses and the uncertainty of achieving profitability; TopoTarget's stage of development as a biopharmaceutical company; government regulation; patent infringement claims against TopoTarget's products, processes and technologies; the ability to protect TopoTarget's patents and proprietary rights; uncertainties relating to commercialization rights; and product liability expo-sure; We disclaim any intention or obligation to

update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.